EHA: Adding Pirtobrutinib to Venetoclax-Rituximab Ups PFS in Chronic Lymphocytic Leukemia

THURSDAY, July 2, 2026-- For patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), adding pirtobrutinib to venetoclax-rituximab (PVR) yields improved progression-free survival (PFS) compared to venetoclax-rituximab (VR)...